SLC5A2 and type 2 diabetes mellitus: Wang et al.36performed a meta-analysis of 29 RCTs3, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117and found no significant difference in VTE risk between T2DM patients receiving SGLT2 inhibitors and those who did not (128/32,038 vs. 92/23,997; RR 0.98, 95% CI 0.75–1.28), with consistent results for DVT and PE separately.